
VANI Stock Forecast & Price Target
VANI Analyst Ratings
Bulls say
Vivani Medical Inc. is positioned favorably due to the promising potential of its candidate NPM-139, which could enhance the safety and tolerability of existing therapies like semaglutide, likely reducing patient discontinuation rates and fostering better dosing compliance. Additionally, the encouraging data showing that NPM-139 has resulted in a sustained weight loss of approximately 20% over six months substantiates its efficacy and market relevance. The advancement of NPM-139 into clinical development is supported by these positive findings, indicative of a strong future for the company's product pipeline.
Bears say
Vivani Medical Inc faces significant risks that contribute to a negative outlook on the company's stock, particularly centered around its lead product, NPM-139. The potential failure of NPM-139 in clinical trials, as well as the inability to gain regulatory approval, poses substantial uncertainty regarding the company's future revenue potential. Additionally, concerns regarding market size, penetration rates, competition, and dilution risk further compound the challenges the company may encounter in achieving commercial success.
This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
VANI Analyst Forecast & Price Prediction
Start investing in VANI
Order type
Buy in
Order amount
Est. shares
0 shares